Reinvigorating stagnant science: Implementation laboratories and a meta-laboratory to efficiently advance the science of audit and feedback by Grimshaw, JM et al.
Grimshaw JM, et al. BMJ Qual Saf 2019;0:1–8. doi:10.1136/bmjqs-2018-008355   1
ReseaRch and RepoRting Methodology
For numbered affiliations see 
end of article.
Correspondence to
Dr JM Grimshaw, Clinical 
Epidemiology Program, Ottawa 
Hospital Research Institute, 
Ottawa ON K1Y 4E9, Canada;  
 jgrimshaw@ ohri. ca
Received 18 May 2018
Revised 8 January 2019
Accepted 12 February 2019
To cite: Grimshaw JM, 
Ivers N, Linklater S, et al. 
BMJ Qual Saf Epub ahead of 
print: [please include Day 
Month Year]. doi:10.1136/
bmjqs-2018-008355
Reinvigorating stagnant science: 
implementation laboratories and a 
meta-laboratory to efficiently 
advance the science of audit 
and feedback
JM grimshaw,   1,2 noah ivers,3,4 stefanie linklater,1 Robbie Foy,5 
Jill J Francis,6 Wouter t gude,   7 sylvia J hysong,   8,9 on behalf of the 
audit and Feedback Metalab
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrAct
Audit and feedback (A&F) is a commonly used quality 
improvement (QI) approach. A Cochrane review 
indicates that A&F is generally effective and leads to 
modest improvements in professional practice but with 
considerable variation in the observed effects. While we 
have some understanding of factors that enhance the 
effects of A&F, further research needs to explore when 
A&F is most likely to be effective and how to optimise 
it. To do this, we need to move away from two-arm 
trials of A&F compared with control in favour of head-
to-head trials of different ways of providing A&F. This 
paper describes implementation laboratories involving 
collaborations between healthcare organisations 
providing A&F at scale, and researchers, to embed 
head-to-head trials into routine QI programmes. This 
can improve effectiveness while producing generalisable 
knowledge about how to optimise A&F. We also describe 
an international meta-laboratory that aims to maximise 
cross-laboratory learning and facilitate coordination of 
A&F research.
GrowinG literAture, stAGnAnt 
Audit And feedbAck science
Audit and feedback (A&F) is a commonly 
used intervention in quality improvement 
(QI) programmes. The latest Cochrane 
systematic review of A&F included 140 
randomised trials and found a median 
absolute improvement of +4% in 
provider performance with an IQR of 
+0.5% to+16%. While A&F is gener-
ally effective for improving professional 
practice, there is substantial variation 
in the observed effects that was only 
partially explained by the effect modifiers 
tested in a meta-regression.1 Cumulative 
meta-analyses indicated that the effect size 
(and IQR) became stable in 2003 after 51 
comparisons from 30 trials.2 By 2011, 47 
additional trials of A&F against control 
were published that did not substantially 
advance our knowledge. Furthermore, 
many of these trials did not incorporate 
A&F features likely to enhance the effec-
tiveness, leading to the suggestion that we 
have a stagnant science despite growing 
literature. As Ioannidis et al point 
out ‘although replication of previous 
research is a core principle of science, 
at some point, duplicative investigations 
contribute little additional value’.3
In this paper, we argue that the field 
has reached this point with A&F research 
and that further two-arm trials of A&F 
against (no A&F) control are unlikely 
to provide additional valuable insights 
and represent a significant opportunity 
cost and research waste.4 Although we 
recognise that there are specific circum-
stances when having a no-intervention 
control might be justified; for example, if 
there are only a small number of studies 
targeting a specific group or setting and 
where there is a good rationale to think 
the group or setting could be an effect 
modifier. Under these circumstances, we 
would suggest that researchers proposing 
a no-intervention control should justify 
their choice.
We argue that future research needs to 
progress from the question ‘in general 
does A&F improve healthcare profes-
sional practice?’ (it does!) to under-
standing how to optimise A&F to 
maximise its effects .5 In short, we need 
to conduct comparative effectiveness of 
head-to-head trials of different variants 
of A&F (eg, to address questions such as 
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how should A&F be formatted? how many behaviours 
should be targeted? what and how many performance 
comparators should be used? how frequently should 
A&F be given?). Often, these variants of A&F have 
little or no cost implications, which means even small 
improvements in the effects of A&F are likely worth-
while at a population level (eg, if we could improve 
effectiveness from say 4% to 6% by simply modifying 
the comparator). We also need head-to-head trials of 
A&F with and without cointerventions (to explore the 
incremental benefits of cointerventions) and head-to-
head trials of A&F compared with other QI interven-
tions (to determine their comparative effectiveness).
Indeed, there is a rich research agenda that needs 
further exploration. Brehaut, Colquhoun and 
colleagues interviewed 28 A&F experts from diverse 
disciplinary backgrounds to identify testable, theo-
ry-informed hypotheses about how to design more 
effective A&F interventions resulting in 15 ‘low 
hanging fruit’ suggestions6 and 313 specific theory-in-
formed hypotheses that could form the basis of an 
initial research agenda.7
no more business As usuAl – let’s chAnGe 
the model
In the business world, this approach is well recognised 
and called radical incrementalism, whereby a series of 
small changes are enacted one after the other resulting 
in radical cumulative changes.8 Similar approaches are 
increasingly being used by behavioural insights units 
to promote evidence-informed public policy.8 As an 
exemplar of what could be done, we highlight the 
Reducing Antibiotic Prescribing in Dentistry (RAPiD) 
trial that evaluated multiple variants of A&F to reduce 
antibiotic prescriptions in Scottish dental community 
practices.9 Under the umbrella of National Health 
Service Education in Scotland, the investigators used 
a partial factorial design to randomise all 795 dental 
practices to four different factors that included 
comparisons of A&F versus control, A&F with or 
without actionable messages, A&F with or without a 
regional performance comparator and A&F provided 
two or three times over a 12-month period. (There 
were no trials of A&F in community dental practices in 
the 2012 Cochrane review justifying an A&F vs no-in-
tervention comparison in the trial; although notably, 
the trial used an unequal randomisation process (4:1) 
in recognition of the likely benefits from A&F.) The 
trial demonstrated that A&F led to a 6% reduction 
in antibiotic prescriptions and that further significant 
reductions were observed if A&F was provided with 
actionable messages and a comparator. However, 
providing feedback three times rather than two times 
was not beneficial.
The switch from two-arm trials of A&F versus 
control to head-to-head trials of different variants of 
A&F has significant implications for the design and 
conduct of trials. In particular, when we evaluate 
different variants of A&F head-to-head trials, we are 
interested in the incremental benefit of the design 
modifications above the general beneficial effect of 
A&F, suggesting that the differential effects are likely 
to be small. Hence, trials need to be powered for small 
effects which require large sample sizes that may be 
difficult to achieve in typical ‘one-off ’ A&F trials 
where researchers need to recruit participating health-
care organisations and professionals. Furthermore, we 
envision that it may be difficult to persuade a research 
funder to fund a very large trial to detect a rela-
tively small (but potentially important incremental) 
effect. Hence, we are sceptical about the feasibility of 
conducting head-to-head trials as one-off projects.
towArds implementAtion lAborAtories
One solution is to establish implementation laborato-
ries.4 Increasingly, healthcare systems and/or organi-
sations are providing A&F to healthcare professionals 
as part of their routine, system-wide QI activities. 
Those designing such A&F programmes must make 
a myriad of decisions about its content, format and 
delivery. Frequently, such programmes do not maxi-
mally use current theories and evidence about how 
to optimise their programmes, given service pres-
sures to ‘do something’ and lack of access to experts 
with theoretical and empirical content expertise. As a 
result, A&F programmes delivered in service settings 
are unlikely to be optimised. Under these circum-
stances, there are opportunities for researchers and 
healthcare system partners to conduct collaborative 
research both to improve the effectiveness of the 
specific A&F programme and to produce generalis-
able knowledge about how to optimise A&F that will 
be relevant to other A&F programmes.
Consider a healthcare system partner that has an 
existing A&F programme (Baseline A&F), but recog-
nises the arbitrary nature of many of its design choices 
and is interested in exploring how to enhance the 
effectiveness of its A&F programme. It could partner 
with researchers to develop A&F B and conduct a 
head-to-head trial of its Baseline A&F against A&F B 
(figure 1) informed by current empirical and theoret-
ical insights10 11 and utilising human-centred design 
approaches.12 Given that the healthcare system 
partner is delivering its A&F programme at scale to 
healthcare organisations and/or professionals, it is 
likely that the trial will have a much larger sample 
size than a trial mounted by researchers who would 
need to recruit healthcare organisations and/or 
professionals. Furthermore, the costs of conducting 
the trial are likely to be modest given that the health-
care system partner is already committed to deliv-
ering A&F at scale and is routinely collecting data 
that could be used for outcome assessment (so the 
marginal costs will largely relate to the design of 
A&F B and trial analysis). If the trial found that 
A&F B was more effective than the Baseline A&F, 
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Figure 1 Schematic representation of sequential trials in an implementation science laboratory. A&F, audit and feedback.
then A&F B would become the standard version of 
A&F for the healthcare system partner. However, it 
is unlikely that all possible variations of interest in 
A&F would be tested in a single trial (even one as 
ambitious as the RAPiD trial), suggesting a need for 
the implementation laboratory to conduct sequential 
trials, programmatically testing a range of variants 
of A&F (eg, informed by Brehaut’s 15 best prac-
tice suggestions6). Hence, the healthcare system 
partner might test A&F B (now the standard prac-
tice) against A&F C, perhaps finding that A&F C 
is less effective, costlier to deliver or less acceptable 
to the target healthcare organisations and/or profes-
sionals and so it is dropped (noting that the health-
care system partner and implementation science 
have learnt from this no-effect study). Following 
this, the healthcare system partner might test A&F B 
against A&F D and so on. Thus, A&F implementa-
tion laboratories involve healthcare system partners 
in continuous improvement using rigorous methods 
to identify more effective A&F variants that can 
be routinely and sustainably embedded into their 
ongoing A&F programmes. Our example above 
uses a series of sequential two-arm trials. However, 
the same approach could be applied to other study 
designs including multi-arm trials, factorial designs 
or balanced incomplete block designs.
Randomised trials are considered the ‘gold stan-
dard’ for determining causal description (‘did strategy 
x lead to outcome y?’)13 because of the following: 
intervention effects are modest; there is an incom-
plete understanding of potential confounders and 
effect modifiers; and there are significant opportu-
nity costs for healthcare systems if ineffective (or 
inefficient) implementation strategies are adopted. 
Although causal description may be sufficient for 
healthcare system partner decisions (‘B was better 
than A, so let’s adopt B’), it provides an incomplete 
picture for advancing implementation science. Given 
our poor understanding of the mechanisms of action, 
potential confounders and effect modifiers of imple-
mentation strategies such as A&F, causal description 
alone is usually inadequate to interpret study find-
ings and determine the generalisability of evalua-
tion findings. However, the conduct of randomised 
trials also provides an opportunity to embed further 
studies to determine the causal explanation (‘how, 
why and under what circumstances did strategy x 
lead to outcome y’)13 to enhance the informative-
ness and generalisability of evaluations including the 
following: study design elements (eg, multi-arm trials, 
factorial designs that allow simultaneous multiple 
comparison9 14); fidelity substudies (to determine 
whether the content of interventions was deliv-
ered as designed, to determine whether participants 
received and/or opened their feedback, to determine 
how participants reacted to the feedback15); mech-
anistic substudies (theory-based process evaluations 
to determine whether interventions activated the 
hypothesised mediating pathways and if so, was this 
sufficient to lead to practice change16); qualitative 
process evaluations (to understand participants’ 
experiences of being in a trial and whether the inter-
vention was acceptable to them17 18) and economic 
evaluations (to determine the cost-effectiveness of 
different A&F strategies19).
There are also opportunities for analytical 
approaches (eg, subgroup analyses and hierarchical 
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regressions) to explore potential effect modifiers in 
inner context variables (eg, healthcare organisation 
or professional characteristics)20 that allow explo-
ration of whether these factors are effect modifiers 
of the A&F (eg, Do teaching hospitals respond to 
A&F similarly to community hospitals? Is baseline 
performance an effect modifier for A&F?) providing 
valuable information for the healthcare system 
partner (Should we vary our feedback approach by 
recipient characteristics?) and for advancing imple-
mentation science. Time series analyses could also 
be undertaken to evaluate the effects of individual 
A&F variants (eg, Did Baseline A&F lead to practice 
change?)21 and to assess learning and decay effects of 
interventions.22
Although we have emphasised A&F design here, 
this approach could be used for other aspects of the 
A&F process, for example evaluating the incremental 
benefit of cointerventions alongside A&F (such as 
educational meetings or computerised prompts) or 
evaluating approaches to improve the receipt and 
uptake of A&F.10
implementation laboratories enable learning 
healthcare systems
Such implementation laboratories are an extension 
of the concept of learning healthcare systems, where 
the learning encompasses generalisable concepts for 
implementation science. As in the physical sciences, 
the laboratory provides an opportunity for experi-
mentation and observation—in this case—of the 
processes playing a role in the uptake of best prac-
tices. However, an implementation science laboratory 
is developed with the express purpose of providing 
applied evidence for the health system partner; 
the engagement of the healthcare system partner 
throughout the process increases the likelihood that 
successful A&F variants are rapidly incorporated 
into the routine practices of the organisation in a 
sustainable way. The embedded nature of A&F labo-
ratories also increases the real-world generalisability 
of any findings given that participants receiving A&F 
from health system partners are likely broadly repre-
sentative of healthcare participants within that juris-
diction. The collaboration allows healthcare system 
partners to access researchers and their expertise 
and allows researchers to access experienced health-
care system personnel who have substantial tacit and 
practical knowledge about providing A&F within 
their system.
By pursuing a research question as prioritised by 
the healthcare system partner, researchers can be 
sure that the topic is one that truly needs addressing, 
and that the measured outcomes are the primary 
ones of interest. The quality of the research design 
and methods can be optimised by implementation 
researchers who are likely to have more experience 
with designing trials that are methodologically robust 
(addressing causal description) and that embed other 
forms of enquiry to maximise the information yielded 
from any trial (addressing causal explanation). This 
partnership capitalises on the expertise of both the 
healthcare system partner and the implementation 
researchers to improve the quality, effectiveness and 
applicability of the trial.
some practical considerations
Many practical issues need to be considered when 
establishing an A&F laboratory. We highlight some 
that are likely to be common across settings.
Need for stability in healthcare system partners
Productive relationships between the health-
care system partner and the research team can be 
disrupted by reorganisation or decommissioning of 
healthcare system partners responsible for QI activ-
ities. Our practical experience suggests a minimum 
of a mutual 3-year commitment to establish a viable 
and functioning laboratory.
Team composition
Teams need the right combination of experts, 
boundary spanners and facilitators. It is important 
to include both senior leadership, who can ensure 
alignment of activities and promote the value of the 
implementation laboratory within the organisation, 
and team members actively involved in the design 
and delivery of the current A&F programmes. Imple-
mentation science is an interdisciplinary team sport; 
a diverse range of research disciplines can maximise 
health system partner and scientific benefits.
Clarifying roles and responsibilities
Time must be invested upfront to build trust, clarify 
roles and expectations and develop clear govern-
ance arrangements to manage the laboratory.23 24 
Although such arrangements will depend on local 
circumstances, resources and norms, it is essential 
that they confer a sense of joint ownership of and 
responsibility for the laboratory between the health 
system partner and the research team.
Identifying shared priorities
It is difficult to fulfill the principles of the implemen-
tation laboratory if the researchers seek to answer 
questions that do not match the goals, timeline or 
budget of the host organisation, or if the host organ-
isation requires a ‘positive’ result. We suggest that 
researchers develop a shortlist of best practices and 
research opportunities for discussion6 7 and negotiate 
the best fit with healthcare system partner needs.
Aligning timelines and activities
Healthcare system partners require lag time to 
embed the testing of variants into their A&F 
cycles, typically to manage practical logistics such 
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as programming and preparing current and variant 
A&F and to ensure alignment with audit cycles. It is 
also worth identifying any potentially competing QI 
activities that may influence trial design, timing or 
interpretation.
Optimising design
Implementation laboratories offer opportunities to 
apply state-of-the-art approaches to A&F design, 
including robust theory-driven and user-centred 
design processes which require time and resources 
usually unavailable to healthcare organisations. 
In A&F laboratories, the lag time required by the 
healthcare system partner provides a widow of 
opportunity for such optimisation.
Ethical considerations
Given that A&F laboratories aim to produce gener-
alisable knowledge (alongside demonstrable service 
improvements), they require adequate research 
ethics oversight and approval before commencing.25 
Healthcare organisations and professionals who 
directly receive the A&F should usually be consid-
ered research participants but not patients who are 
only indirectly affected by the feedback. Altered or 
waived consent from research participants may be 
feasible if the intervention and study procedures 
could be considered minimum risk (which is likely 
given that variants of A&F are being tested), no 
identifiable private information about participants 
is released to the study team (which seems feasible 
to ensure), consent would not be feasible (which is 
likely given the large number of healthcare organisa-
tions and professionals) or if awareness of the study 
might invalidate its results.
Funding
Although the costs of implementation laboratories 
are likely to be significantly less than the costs of 
conducting one-off research projects, there will be 
additional costs for the healthcare system partner 
from designing and delivering two different vari-
ants of A&F. Nevertheless, we believe that research 
funders are more likely to fund a programme of 
research to optimise A&F working with and lever-
aging resources of healthcare system partners.
why stop there? let’s build the metA-
lAborAtory
Individual implementation laboratories cannot 
adequately address the remaining uncertainties 
around A&F for a number of reasons. First, an 
individual laboratory will only be able to evaluate 
a limited number of A&F variants. Second, imple-
mentation science is interested in the generalisability 
of findings from individual laboratories suggesting 
the need for replication across other settings. Finally, 
while inner context variables are likely to vary 
within an individual laboratory, the outer context 
variables (eg, governance, accountability and reim-
bursement arrangements)20 are likely to be common 
across healthcare organisations and/or professionals 
receiving A&F. As such, individual laboratories 
cannot inform us about the likely impact of these 
outer context variables on the effectiveness of A&F.
Fully addressing the remaining uncertainties 
around A&F may require a ‘meta-laboratory’ 
approach: a coordinated set of implementation labo-
ratories, in which findings from interventions tested 
in one context could inform decisions for another 
context, to facilitate a cumulative science in the 
field. This approach would allow for shared exper-
tise, opportunities for planned replication to explore 
replicability and outer context issues and would build 
an international community of healthcare system 
partners with shared interests. The meta-laboratory 
would contribute to the reduction of research waste 
through this shared expertise and planned replica-
tion as study results and insights from one implemen-
tation laboratory can be used to inform study design 
and conduct for another implementation laboratory.
A meta-laboratory could form a collaborative 
space encouraging linkages between researchers 
undertaking innovative theoretical7 or develop-
mental work26–28 with researchers in implementa-
tion laboratories to ensure the timely translation of 
promising innovations into large-scale evaluations 
within implementation laboratories. Meta-laborato-
ries could provide state-of-the-art, regularly updated 
resources for both healthcare systems planning A&F 
activities and researchers planning future research 
studies (including promoting full and transparent 
reporting of laboratories activities).
Announcing the Audit and feedback metalab
There are an increasing number of A&F laboratories 
globally (see table 1). We have established the Audit and 
Feedback MetaLab involving researchers and laborato-
ries from five countries (Australia, Canada, the Nether-
lands, the UK and the USA). To date, the Audit and Feed-
back MetaLab has held annual international symposia 
(Ottawa 2016, Leeds 2017, Toronto 2018 and another 
planned in Amsterdam 2019) each involving a scien-
tific meeting and an open meeting with training activ-
ities for healthcare systems and organisations delivering 
A&F programmes. We have established a website ( www. 
ohri. ca/ auditfeedback) providing a ‘one-stop shop’ of 
resources about designing and evaluating A&F.
implementation laboratories and meta-laboratories: a 
generalisable approach?
We recognise that A&F is only one of many implemen-
tations strategies that healthcare systems are interested 
in to improve healthcare delivery. However, there are 
similar challenges faced by healthcare systems interested 
in using other implementation strategies (eg, educational 
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Table 1 Participating implementation laboratories in the A&F MetaLab
Laboratory Health system partner A&F interventions tested Evaluation design
AFFINITIE—enhanced A&F 
interventions to increase 
the uptake of evidence-
based transfusion practice
National Comparative 
Audit of Blood 
Transfusion, UK
 ► Enhanced feedback report content (eg, 
streamlining formatting, highlighting gaps 
between current and recommended practice, and 
suggesting practical action plans)
 ► Enhanced ‘follow on’ support for local action 
(ie, a web-based toolkit for use by hospital 
transfusion teams and telephone support to 
increase engagement)
 ► Two linked and sequential cluster randomised 2×2 
factorial trials with parallel process and economic 
evaluations
 ► 147 and 137 hospitals
BORN MND—Better 
Outcomes Registry & 
Network Ontario- Maternal 
Newborn Dashboard
Better Outcomes Registry 
& Network, Ontario, 
Canada
 ► A&F provided via the MND which consists of near 
real-time hospital-specific feedback about six key 
performance indicators, peer comparison data, a 
visual display of practice gaps and benchmarks to 
provide direction for practice change
 ► Evidence summaries are also provided for each of 
the key performance indicators.
Mixed methods:
 ► Interrupted time series analysis using population-
based data from all maternal newborn hospitals 
in Ontario covering a 3- year period before 
implementation of the MND and 2.5 years after
 ► Provincial survey of all hospitals and site visits with 
a diverse sample of hospitals to identify barriers 
and facilitators to use of the MND and determine 
factors that influence uptake to trigger and 
facilitate practice change
 ► 96 hospitals
Implementing Goals of 
Care Conversations with 
Veterans in Veteran Affairs 
(VA) Long Term Care 
Settings
Health system partner:
VA Corporate Data 
Warehouse; VA National 
Centre for Ethics in 
Healthcare, USA
 ► Electronically generated feedback reports 
providing feedback on performance in 
documenting goals of care conversations, 
coupled with learning collaboratives
 ► Different formats and delivery of feedback reports 
will be tested
 ► Quasi-experimental mixed-methods design using 
interrupted time series
NICE foundation electronic 
quality dashboard with 
action implementation 
toolbox to enhance quality 
of pain management in 
Dutch intensive care units
NICE quality registry, the 
Netherlands
 ► Online quality dashboard
 ► Intervention group additionally receives access 
to an integrated action implementation toolbox 
of suggested actions and materials to further 
support the development and management of 
action plans
 ► Two-arm cluster randomised controlled trial with 
the same 21 ICUs allocated to feedback without 
or feedback with action implementation toolbox 
group
 ► Both arms receive telephone support to increase 
engagement
 ► 21 intensive care units; 72 individual professionals
OHIL—Ontario Healthcare 
Implementation Laboratory: 
Improving the impact of 
Practice Reports in nursing 
homes
Health Quality Ontario, 
Canada
 ► Variation in comparators featured in the feedback 
reports (eg, overall provincial average prescribing 
rate versus the 25th percentile prescribing rate)
 ► Variation in the framing of the content as 
positive or negative (eg, recipients may be 
told they have prescribed potentially harmful 
medications to 15% of their patients versus 
avoiding prescription-related harms in 85% of 
their patients)
 ► Cluster randomised 2×2 factorial trial with 
embedded mixed-method process evaluation
 ► Prescribers receive three iterations of the report
 ► Prescribers receive surveys and may also participate 
in interviews to assess mechanism of action and 
additional barriers to use of reports to make 
changes
TRIADS—Translation 
Research in a Dental 
Setting
NHS Education Scotland  ► Enhanced feedback report content (eg, changing 
comparators)
 ► Enhanced persuasive messaging using behaviour 
change techniques
 ► Timing of feedback
 ► Impact of educational outreach visits in addition 
to audit
 ► Enhanced audits using behaviour taxonomy 
approaches
 ► Cluster randomised (sometimes factorial trials) are 
conducted whenever possible
 ► Time series are also used to monitor impact of 
national audits.
A&F, audit and feedback; ICUs, intensive care units; MND, Maternal Newborn Dashboard; NHS, National Health Service; NICE, National Intensive Care 
Evaluation.
outreach) and by healthcare organisations interested in 
using Plan-Do-Study-Act cycles to improve quality. The 
model of implementation laboratories and an interna-
tional meta-lab could be equally applied to understand 
how to optimise these strategies. There are also exam-
ples of implementation laboratories addressing imple-
mentation challenges in specific sectors or jurisdictions 
(the Translation Research in a Dental Setting labora-
tory which is developing and evaluating implemen-
tation strategies alongside guideline development for 
community dentists in Scotland29 and the Hunter Valley 
Population Health laboratory which uses state-of-the-art 
implementation science approaches to design and eval-
uate population health interventions in Australia).30
conclusions
Despite widespread application, we are only beginning 
to understand how, when and why implementation 
interventions such as A&F might work best. Publi-
cations describing evaluations of these interventions 
may provide a snapshot of a local change initiative, 
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but rarely offer the sort of detail needed to ascertain 
potentially generalisable findings regarding mechanisms 
for achieving change.31 We urgently need to develop 
the scientific basis for A&F (and other QI interven-
tions) informed by behavioural and system theory and 
using rigorous, large-scale evaluations. Implementation 
science laboratories provide an opportunity to reinvig-
orate the field by supporting healthcare system partners 
to optimise their own A&F programmes while effi-
ciently advancing the scientific basis of A&F. This paper 
demonstrates that productive implementation science 
laboratories are feasible and that they can be mutu-
ally beneficial for both implementation scientists and 
health system partners. We hope it is received as a call 
to action for those organisations involved in the design 
and delivery of A&F, for scientists interested in driving 
forward related scientific findings, and for research 
funders interested in maximising impact in both these 
domains. The Audit and Feedback MetaLab can facili-
tate communication and collaboration across individual 
laboratories and act as a resource for healthcare systems 
planning A&F programmes while providing evidence on 
the generalisability of scientific evidence found at local 
A&F laboratories.
Author affiliations
1Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, 
Ontario, Canada
2Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
3Women’s College Research Institute, Women’s College Hospital, Toronto, 
Ontario, Canada
4Department of Family Medicine and Community Medicine, University of 
Toronto, Toronto, Ontario, Canada
5Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
6Health Services Research and Management Division, City University of London, 
London, UK
7Department of Medical Informatics, Academic Public Health Research Institute, 
Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
8Center for Innovations in Quality Effectiveness and Safety, Michael E. DeBakey 
Veterans Affairs Medical Center, Houston, Texas, United States
9Section of Health Services Research, Department of Medicine, Baylor College 
of Medicine, Houston, Texas, United States
Correction notice This article has been corrected since it 
published Online First. The 'on behalf of' clause has been 
reinstated as it got ommitted in the previous version.
Acknowledgements Jeremy Grimshaw holds a Canada 
Research Chair in Health Knowledge Transfer and Uptake. 
Noah Ivers is supported by the Women’s College Hospital 
Chair in Implementation Science and a Clinician Scientist 
award from the Department of Family and Community 
Medicine at the University of Toronto.
Collaborators On behalf of the Audit & Feedback MetaLab. 
Sarah Alderson, Sylvain Boet, Jamie Brehaut, Benjamin Brown, 
Jan Clarkson, Heather Colquhoun, Nicolette de Keizer, Laura 
Desveaux, Gail Dobell, Sandra Dunn, Amanda Farrin, Robbie 
C Foy, Jill J Francis, Anna Greenberg, Jeremy M Grimshaw, 
Wouter T Gude, Suzanne Hartley, Tanya Horsley, Sylvia J 
Hysong, Noah M Ivers, Zach Landis-Lewis, Stefanie Linklater, 
Jane London, Fabiana Lorencatto, Susan Michie, Denise 
O’Connor, Niels Peek, Justin Presseau, Craig Ramsay, Anne E. 
Sales, Ann Sprague, Simon Stanworth, Michael Sykes, Monica 
Taljaard, Kednapa Thavorn, Mark Walker, Rebecaa Walwyn, 
Debra Weiss, Thomas A Willis and Holly Witteman.
Contributors This paper is the product of the A&F MetaLab. 
The named authors are the current Steering Group of the 
MetaLab. The group authors have contributed consistently 
to the development of these ideas over the last 3 years during 
several national and international meetings (Ottawa Canada 
2016, Leeds UK 2017, Calgary Canada 2017). All authors have 
been involved in drafting of the paper and have approved the 
final version. JMG is the guarantor for the paper.
Funding This study was funded by the Canadian Institutes of 
Health Research (FDN-143269).
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally 
peer reviewed.
Open access This is an open access article distributed in 
accordance with the Creative Commons Attribution Non 
Commercial (CC BY-NC 4.0) license, which permits others 
to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different 
terms, provided the original work is properly cited, appropriate 
credit is given, any changes made indicated, and the use is non-
commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4.0
references
 1 Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: 
effects on professional practice and healthcare Outcomes. 
Cochrane Database Syst Rev 2012;154.
 2 Ivers NM, Grimshaw JM, Jamtvedt G, et al. Growing 
literature, stagnant science? Systematic review, meta-regression 
and cumulative analysis of audit and feedback interventions in 
health care. J Gen Intern Med 2014;29:1534–41.
 3 Ioannidis JPA, Greenland S, Hlatky MA, et al. Increasing value 
and reducing waste in research design, conduct, and analysis. 
Lancet 2014;383:166–75.
 4 Ivers NM, Grimshaw JM. Reducing research waste with 
implementation laboratories. The Lancet 2016;388:547–8.
 5 Ivers NM, Sales A, Colquhoun H, et al. No more ‘business 
as usual’ with audit and feedback interventions: towards an 
agenda for a reinvigorated intervention. Implementation Sci 
2014;9.
 6 Brehaut JC, Colquhoun HL, Eva KW, et al. Practice feedback 
interventions: 15 suggestions for optimizing effectiveness. Ann 
Intern Med 2016;164:435–41.
 7 Colquhoun H, Michie S, Sales A, et al. Reporting and design 
elements of audit and feedback interventions: a secondary 
review. BMJ Qual Saf 2017;26:54–60.
 8 Halpern D, Mason D, Radical incrementalism MD. Radical 
incrementalism. Evaluation 2015;21:143–9.
 9 Elouafkaoui P, Young L, Newlands R, et al. An audit and 
feedback intervention for reducing antibiotic prescribing 
in general dental practice: the rapid cluster randomised 
controlled trial. PLoS Med 2016;13:e1002115.
 10 Gould NJ, Lorencatto F, Stanworth SJ, et al. Application 
of theory to enhance audit and feedback interventions to 
increase the uptake of evidence-based transfusion practice: 
an intervention development protocol. Implementation Sci 
2014;9.
 11 Ivers NM, Desveaux L, Presseau J, et al. Testing feedback 
message framing and comparators to address prescribing 
of high-risk medications in nursing homes: protocol for a 
pragmatic, factorial, cluster-randomized trial. Implementation 
Science 2017;12.
 12 Witteman HO, Presseau J, Nicholas Angl E, et al. Negotiating 
tensions between theory and design in the development of 
 o
n
 21 M
arch 2019 by guest. Protected by copyright.
http://qualitysafety.bmj.com/
BM
J Qual Saf: first published as 10.1136/bmjqs-2018-008355 on 9 March 2019. Downloaded from 
8 Grimshaw JM, et al. BMJ Qual Saf 2019;0:1–8. doi:10.1136/bmjqs-2018-008355
Research and Reporting Methodology
Mailings for people recovering from acute coronary syndrome. 
JMIR Hum Factors 2017;4:e6.
 13 Shadish WR, Cook TD, Experimental CDT. Quasi-
experimental designs for generalized causal inferences. 
Houghton Mifflin Company, 2002.
 14 Hartley S, Foy R, Walwyn REA, et al. The evaluation of 
enhanced feedback interventions to reduce unnecessary blood 
transfusions (AFFINITIE): protocol for two linked cluster 
randomised factorial controlled trials. Implement Sci 2017;12.
 15 Lorencatto F, Gould NJ, McIntyre SA, et al. A 
multidimensional approach to assessing intervention fidelity 
in a process evaluation of audit and feedback interventions 
to reduce unnecessary blood transfusions: a study protocol. 
Implement Sci 2016;11.
 16 Ramsay CR, Thomas RE, Croal BL, et al. Using the theory of 
planned behaviour as a process evaluation tool in randomised 
trials of knowledge translation strategies: a case study from UK 
primary care. Implementation Sci 2010;5.
 17 Dunn S, Sprague AE, Grimshaw JM, et al. A mixed methods 
evaluation of the maternal-newborn dashboard in Ontario: 
dashboard attributes, contextual factors, and facilitators and 
barriers to use: a study protocol. Implementation Science 
2015;11.
 18 Sekhon M, Cartwright M, Francis JJ. Acceptability of 
healthcare interventions: an overview of reviews and 
development of a theoretical framework. BMC Health Serv Res 
2017;17.
 19 Sculpher M. Evaluating the cost-effectiveness of interventions 
designed to increase the utilization of evidence-based 
guidelines. Family Practice 2000;17:26S–31.
 20 Damschroder LJ, Aron DC, Keith RE, et al. Fostering 
implementation of health services research findings 
into practice: a consolidated framework for advancing 
implementation science. Implementation Sci 2009;4.
 21 Guthrie B, Kavanagh K, Robertson C, et al. Data feedback 
and behavioural change intervention to improve primary care 
prescribing safety (EFIPPS): multicentre, three arm, cluster 
randomised controlled trial. In: BMJ (clinical research). , 
2016: 354, i4079.
 22 Ramsay CR, Eccles M, Grimshaw JM, et al. Assessing the long-
term effect of educational reminder messages on primary care 
radiology referrals. Clin Radiol 2003;58:319–21.
 23 Donsbach JS, Tannenbaum SI, Mathieu JE, et al. A review 
and integration of team composition models. moving toward 
a dynamic and temporal framework. Journal of Management 
2014;40:130–60.
 24 Salas E, Shuffler ML, Thayer AL, et al. Understanding and 
improving teamwork in organizations: a Scientifically based 
practical guide. Hum Resour Manage 2015;54:599–622.
 25 Weijer C, Grimshaw JM, Eccles MP, et al. The Ottawa 
statement on the ethical design and conduct of cluster 
randomized trials. PLoS Med 2012;9:e1001346.
 26 Gude WT, van Engen-Verheul MM, van der Veer SN, et al. 
How does audit and feedback influence intentions of health 
professionals to improve practice? a laboratory experiment 
and field study in cardiac rehabilitation. BMJ Qual Saf 
2017;26:279–87.
 27 Gude WT, Roos-Blom M-J, van der Veer SN, et al. Electronic 
audit and feedback intervention with action implementation 
toolbox to improve pain management in intensive care: 
protocol for a laboratory experiment and cluster randomised 
trial. Implement Sci 2017;12.
 28 Gude WT, van der Veer SN, van Engen-Verheul MM, et al. 
Inside the black box of audit and feedback: a laboratory study 
to explore determinants of improvement target selection by 
healthcare professionals in cardiac rehabilitation. Stud Health 
Technol Inform 2015;216:424–8.
 29 Clarkson JE, Ramsay CR, Eccles MP, et al. The translation 
research in a dental setting (triads) programme protocol. 
Implementation Science 2010;5.
 30 Wolfenden L, Yoong SL, Williams CM, et al. Embedding 
researchers in health service organizations improves research 
translation and health service performance: the Australian 
Hunter New England population health example. J Clin 
Epidemiol 2017;85:3–11.
 31 Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from 
incomplete or unusable reports of biomedical research. The 
Lancet 2014;383:267–76.
 o
n
 21 M
arch 2019 by guest. Protected by copyright.
http://qualitysafety.bmj.com/
BM
J Qual Saf: first published as 10.1136/bmjqs-2018-008355 on 9 March 2019. Downloaded from 
